TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05319756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 600 mg
Description: Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg
Description: Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 600 mg and oxycodone HCl 20 mg
Description: Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg and oxycodone HCl 20 mg
Description: Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone HCl 20 mg
Description: Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
Study: NCT05449925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable PRF and Microneedling
Description: i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
Study: NCT06093724

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static and dynamic perineo-pelvic MRI
Description: Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
Study: NCT05289037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.617.2
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized S protein of the B.1.617.2 (Delta) variant SARS-CoV-2 strain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection
Study: NCT05393375

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05289037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection
Study: NCT05902286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSC+
Description: The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: OSC-
Description: During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
Study: NCT05881824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MDG intervention
Description: 6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
Study: NCT06328673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM919
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM919
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM919
Description: Anti-MICA/MICB monoclonal antibody
Study: NCT05274906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat
Description: Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat
Description: Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
Study: NCT06567496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Resort
Description: First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be used as an intervention to help manage stress, worry, and sadness. It is grounded on evidence-based cognitive behavioral therapy and acceptance and commitment therapy techniques, including psychoeducation, mindfulness, behavioral activation through values clarification and goal setting, and cognitive reframing to identify and reframe cognitive distortions.
Study: NCT04753879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza
Study: NCT06085586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Weight Bearing
Description: Full weight bearing (100%) initiated at 4 weeks postoperatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Weight Bearing
Description: Full weight bearing (100%) initiated at 6 weeks postoperatively
Study: NCT05964400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: duoABLE
Description: Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
Study: NCT06163898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT05006313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescence angiography
Description: Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
Study: NCT05543629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986442
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemexetred
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study: NCT05570721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
Study: NCT05285553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight 1 Day
Description: Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proclear 1 day
Description: Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year.
Study: NCT05843253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib PO qd on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib PO qd on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib PO qd on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib PO qd on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus PO qd on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus PO qd on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus PO qd on days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus PO qd on days 1-28
Study: NCT06558682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin and Cisplatin
Description: Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
Study: NCT05364164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-L01 12.5/1,000 mg
Description: FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-L01 12.5/1,000 mg
Description: FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
Study: NCT06421662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Training
Description: The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak.
Study: NCT05865002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR107
Description: Once daily
Study: NCT05654116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Interaction Profile (CIP) training
Description: The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
Study: NCT06325072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conclusive genetic testing
Description: Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genotype-phenotype correlation for personalized diagnosis
Description: Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip
Description: The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
Study: NCT06328673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM919
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study: NCT04205526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: Patients randomized to receive actual rTMS treatment will receive 1Hz rTMS applied over contralesional M1 at an intensity of 120% resting motor threshold once daily for 30 minutes (approximately 1800 pulses) for a total of 15 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: For sham-stimulation, the TMS coil will be placed over the inter-hemispheric fissure at the vertex and stimulation will be performed with low intensity (10% resting motor threshold). This will cause similar skin sensations as real stimulation but will not induce currents in motor relevant areas.
Study: NCT05580081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-CAN
Description: online support and consultation to providers
Study: NCT06192225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre-trained guided slow paced breathing (~6 breaths per minute)
Description: Slow PACE breathing
Study: NCT06334887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of esTOCma
Description: Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged.